Effect of Increased Pain Tolerance on Exercise Performance

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

16 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-01

Study Completion Date

2019-03-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical prescription and use of opioids is a clear problem in large parts of the world and has the recent years received an increasing publicity in sports. This is in particular due to the World Anti-Doping Agency monitoring list, which reveal that endurance athletes utilize the opioid Tramadol frequently with the aim to enhance performance according to anecdotal evidence.

Studies investigating the effect of tramadol on exercise performance in healthy humans is limited to one study in moderate trained subjects. However, this effect may be different in highly trained subjects due to the effects of chronic exercise. Furthermore, ingestion of tramadol may impact motor-cognitive performance and it remains unknown whether tramadol can be detected in highly trained subjects following exercise.

In the present study the investigators apply a randomized double-blind placebo-controlled counterbalanced cross-over design to investigate whether tramadol treatment improves a preloaded cycling time trial performance, whether it affects motor-cognitive performance and whether it is detectable following exercise.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Tramadol as a Treatment for Opioid Addiction

NCT00301210

Opioid-Related Disorders

COMPLETED PHASE1/PHASE2

Attenuation of Pain in Men and Women

NCT01220414

Pain

COMPLETED NA

Effect of Duloxetine and Venlafaxine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol: A Three-phase Randomized Balanced Cross-over Study in Healthy Volunteers

NCT01443520

Healthy

COMPLETED PHASE4

The Effect of Codeine on Driving Abilities

NCT00477178

Healthy

COMPLETED

Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol

NCT01214941

Pharmacokinetics Pharmacodynamics

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Opioid Use Exercise

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tramadol treatment

Group Type EXPERIMENTAL

Tramadol

Intervention Type DRUG

The subjects will orally ingest 100 mg tramadol retard actavis

Placebo treatment

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type OTHER

The subjects will orally ingest 100 mg calcium powder

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tramadol

The subjects will orally ingest 100 mg tramadol retard actavis

Intervention Type DRUG

Placebo

The subjects will orally ingest 100 mg calcium powder

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Maximal oxygen uptake \< 55 ml O2/min/kg
* Plasma creatinine concentration between 60-105 umol/L
* Plasma alanine aminotransferase between 10-70 U/L
* Familiarized with endurance training for at least a few years